A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

This study tests BL-B01D1 (a targeted antibody-drug conjugate) combined with a PD-1 immunotherapy drug in patients with head and neck squamous cell carcinoma that has returned or spread, as well as other solid tumors. The treatment aims to use the immune system alongside a targeted chemo payload to fight the cancer. **You may be eligible if...** - You are between 18 and 75 years old - You have recurrent or metastatic head and neck squamous cell carcinoma (not nasopharyngeal cancer) or another eligible solid tumor, confirmed by biopsy - You have at least one measurable tumor - You have not previously received systemic treatment for your recurrent or metastatic disease - Your expected survival is at least 3 months - You are in good general health (ECOG score 0–1) **You may NOT be eligible if...** - You have previously received a topoisomerase I inhibitor-based ADC drug - You previously had a severe immune-related reaction (grade 3 or higher) from immunotherapy - You are on systemic corticosteroids or immunomodulatory drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.